MedTrace Logo

Busulfan Sample Collection Study

NCT05711732 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-04-03

No results posted yet for this study

Summary

Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.

Conditions

  • Subjects Treated With Busulfan

Interventions

DIAGNOSTIC_TEST

MyCare Oncology Busulfan Assay Kit

This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.

Sponsors & Collaborators

  • Saladax Biomedical, Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-08
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05711732 on ClinicalTrials.gov